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Preventive strategies in endothelin-induced renal failure. The
endothelial vasoconstrictor endothelin (ET) can induce acute
renal failure when fibrinolysis and vasodilatory prostanoids (PGs)
are inhibited. This study compares therapeutic agents preventing
ET-induced acute renal failure in anesthetized female pigs. We
investigated the effect of four ET boli (1.5 mg/kg, i.v.) after
pretreatment with indomethacin (2 mg/kg) and e-aminocapro-
icacid (100 1 50 mg/kg) alone (controls, group 1) or during
additional nifedipine (10 mg/kg/h; group 2), hirudin (0.5 mg/kg;
group 3), or enalapril (2 3 0.15 mg; group 4) on coagulation, PGs,
and renal function. The ET-induced blood pressure increase was
lower in groups 2 to 4 (lowest in group 3, P , 0.05). PG synthesis
was blocked in all groups. The initial hypercoagulability (controls)
resulted in disseminated intravascular coagulation that was pre-
vented by hirudin and was attenuated in groups 2 and 4. At the
end of the experiment, creatinine clearance was significantly (P ,
0.05) decreased. The recovery of renal function two hours after
the last ET bolus was most pronounced in the hirudin group. All
therapeutic drugs attenuated ET-induced impairment of renal
function. Hirudin seems to be the most potent protective drug.
Prevention of further ET release evoked by ET-mediated secre-
tion of thrombin might explain this. These results suggest three
important pathways for ET’s hemodynamic and renal effects.
Beside its vasoactive effects, endothelin (ET) interacts,
especially in the kidney, with the prostaglandin (PG)
system and the endogenous coagulation system. Previous
studies have shown that when protective fibrinolysis and
PG synthesis are inhibited, exogenous administration of ET
to plasma levels two to three times higher than in healthy
subjects can induce renal failure [1]. Such high levels occur
in disease states such as hepatorenal syndrome and septic
shock. In this model, we compared the effect of a calcium
channel blocker [nifedipine (NIF)], a direct thrombin an-
tagonist [hirudin (HIR)], and an angiotensin-converting
enzyme inhibitor [enalapril (ENAL)] on ET-induced
changes in renal function, blood coagulation, and hemody-
namics. HIR was used because of the well-documented
activation of ET release by thrombin [2, 3].
METHODS
Female, domestic, Go¨ttingen-bred pigs (33.4 6 2.5 kg,
N 5 20) were premedicated with ketamine (20 mg/kg, i.m.)
and atropine (0.02 mg/kg, i.m.), anesthetized with piritra-
mide (10 mg i.v. plus 0.1 mg/kg/hr i.v.), and ventilated with
O2, N2O, and halothane using a positive-pressure respira-
tor. The right internal carotid artery was connected to a
transducer system for continuous analysis of blood pressure
(BP) and heart rate. After three 20-minute blood samples
for baseline measurements, the experiment was started.
Drugs were given i.v. at fixed times in four groups. All
groups received ET (1.5 mg/kg; 0, 60, 120, and 180 min-
utes), indomethacin (2 mg/kg, to inhibit PG synthesis, 210
min), e-aminocaproicacid (100 1 50 mg/kg to inhibit fibri-
nolysis, 215 and 105 minutes). Group 1 (control) received
no other drugs. Group 2 received NIF (10 mg/kg/h, 210
min), and group received 3 ENAL (2 3 0.15 mg, 210 and
110 min) and group 4 HIR (0.5 mg/kg, 210 and 110 min).
Blood gas analysis, electrolyte, and creatinine clearance
measurements were performed hourly. At 10, 30, and 60
minutes after each ET bolus, blood samples were taken for
determination of plasma-renin activity, 6-keto-PGF1a,
PGE2, thromboxane-B2, ET-1, and coagulation parame-
ters. ET and plasma renin activity were measured by
radioimmunoassay, plasma PGs by enzyme immunoassay,
coagulation parameters as described elsewhere [4], and
proteinuria by a nephelometer analyzer (Behringwerke,
Marburg, Germany). Statistical analysis was carried out
using commercial software (SAS, Cary, NC, USA). The
normal distribution of variables was tested by the Shapiro-
Wilk test. If the variable was normally distributed, the t-test
for paired samples was used. If not, the Wilcoxon matched-
pairs rank test was applied. Significance was set at P , 0.01
for blood gas analysis and proteinuria and P , 0.05 for
other parameters.
RESULTS AND DISCUSSION
In all groups, the second ET bolus evoked the largest BP
increase: in controls increase was from (systolic/diastolic)
88.6/61.6 6 13.1/15.9 to 189.6/142.3 6 4.5/13.5 mm Hg.
HIR had the strongest antihypertensive effect. (BP after
the second ET bolus was 139.2/107 6 15.6/12.8 mm Hg.)
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NIF and ENAL reduced the maximum increase in BP by
about 15 mm Hg. ET elicited a continuous decrease in
blood pH and standard bicarbonate during the experiment,
with different degrees of recovery in the postdrug period.
At 240 minutes, significant proteinuria was present in all
groups, with good recovery in groups 2 to 4 (total recovery
in group 4) and an ongoing increase up to 912.6 6 275.3
mg/liter in controls. At the end of the experiment, creati-
nine clearance was decreased in all groups with maximum
decrease in controls followed by groups 2 and 4. Creatinine
clearance in groups 2, 3, and 4 recovered to baseline in the
postdrug period, compared with 40.5 6 15.4 ml/min in
group 1 (Fig. 1). Plasma ET was significantly lower in the
treatment groups than in control, especially in the NIF and
the HIR groups. ET activated the endogenous coagulation
system, resulting in disseminated intravascular coagulation
in controls [lengthening of the activated partial thrombo-
plastin time, a decrease in antithrombin III (AT III) and
factor VIII activity after a transient slight increase after the
first three ET boli]. These effects were attenuated in groups
2 and 4 and abolished in group 3 in which activated partial
thromboplastin time was lengthened initially to 42.4 6 3.32
seconds and subsequently returned to baseline at the end of
the experiment.
To summarize the findings, all therapeutic drugs had a
hypotensive effect. NIF blocks the voltage-operated dihy-
dropyridine-sensitive Ca1 channels activated by ET [5].
Other studies have shown that NIF inhibits ET-stimulated
renin release [6]. ENAL inhibits basal and stimulated
secretion of ET [7], possibly through an increase of endog-
enous nitric oxide (NO) via bradykinin. A further possibil-
ity is inhibition of the renin-angiotensin system by inhibi-
tion of angiotensin-converting enzyme and weakening of
ET-induced potentiation of the vasoconstrictive effects of
Ang II. ENAL achieved the greatest protection against
ET-induced metabolic acidosis and proteinuria, which em-
phasizes the importance of an intact renal endothelium and
adequate glomerular blood flow. Through its preferential
vasodilatory effect on the efferent arterioles mainly medi-
ated by NO and bradykinin, ENAL protects the glomerulus
against the massive ET-induced BP increase [8, 9]. The
remarkable effects of HIR are still not completely under-
stood. Thrombin inhibits the neutral endopeptidase that is
responsible for the degradation of peptide hormones such
as ET [2]. HIR, as a direct inhibitor of thrombin, might
abolish these effects and accelerate degradation of ET. In
view of the ET-induced increase in thrombin-antithrombin
complexes and decrease in AT III activity [10], the lower
plasma ET-levels and the attenuated decrease in AT III
levels in the HIR group also support these considerations.
These data show clearly the interaction of coagulation and
endothelium-derived vasoactive factors such as ET. A
diffuse microthrombosis induced by the activation of coag-
ulation also may play a role in the reduction of renal
function. This effect, as well as the ET-induced BP in-
crease, might be affected by HIR therapy, preventing
further ET release evoked by ET-mediated secretion of
thrombin.
In conclusion, HIR seems to be the most potent protec-
tive drug. The prevention of further ET release evoked by
ET-mediated secretion of thrombin could serve as an
explanation. The efficacy of all therapeutic drugs suggests
three important pathways of ET’s hemodynamic and renal
effects.
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Abbreviations used in this article are: AT III, antithrombin III; BP,
blood pressure; ENAL, enalapril; ET, endothelin; HIR, hirudin; PG,
prostaglandin; NIF, nifedipine; NO, nitric oxide.
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Fig. 1. Creatinine clearance in the
experimental groups. After a 60-minute
equilibration period, all groups received
indomethacin (IM; 2 mg/kg, 210 minutes) and
e-aminocaproic acid (100 1 50 mg/kg, 215 and
105 minutes). Group 1 (left) received no other
pretreatment. Group 2 (left center) received
additional nifedipine (NIF; 10 mg/kg/h, starting
at 210 minutes), whereas group 3 (right center)
received hirudin (HIR; 0.5 mg/kg, 210 and 110
minutes), and group 4 (right) received enalapril
(ENAL; 2 3 0.15 mg/kg, 210 and 110 minutes).
All groups were given four boli (0, 60, 120, and
180 minutes) of endothelin (ET; 1.5 mg/kg). For
each group, the three bars represent the times: 0,
240, and 300 minutes. The shaded area represents
the value. The open area represents the SD. *P ,
0.05 versus 0 minutes.
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